Opinion

Video

Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer

Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.

Manali Bhave begins by discussing first-line therapy for HER2-positive metastatic breast cancer, which is typically taxane chemotherapy (like docetaxel or paclitaxel) plus trastuzumab and pertuzumab. She cites the pivotal CLEOPATRA trial that established this dual HER2 blockade regimen as the standard of care, demonstrating significantly improved progression-free and overall survival compared to chemotherapy and trastuzumab alone.

Bhave highlights the 8-year landmark data showing an impressive 37% overall survival rate with the dual blockade regimen versus 23% in the control arm. She notes that docetaxel is preferred, but weekly paclitaxel can be used if docetaxel is not tolerated well.

When asked by Spring if alternative regimens are ever considered instead of taxane/trastuzumab/pertuzumab, Spring acknowledges the impressive CLEOPATRA results but mentions a rare case where she used trastuzumab/chemotherapy without pertuzumab for an oligometastatic presentation in an older patient never previously exposed to HER2 therapy.

They then discuss getting baseline brain MRIs in HER2+ metastatic breast cancer. Bhave does not routinely get them but considers it in very high-risk cases with aggressive disease and rapid metastatic recurrence after adjuvant therapy, as that could guide using regimens with good CNS penetration. Spring agrees with this approach.

This summary was AI-generated and edited for clarity.

Related Videos
Sheldon M. Feldman, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.